Pharm Sci. 2021;27(4): 560-567.
doi: 10.34172/PS.2021.14
  Abstract View: 244
  PDF Download: 115

Research Article

The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial

Sajad Khiali 1 ORCID logo, Parvin Sarbakhsh 2, Sina Mashayekhi 3, Elham Mohamadrezapour 1, Samaneh Dousti 3, Taher Entezari-Maleki 1,4* ORCID logo

1 Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Department of Statistics and Epidemiology, Faculty of Public Health, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Pediatrics, Islamic Azad University, Tabriz, Iran.
4 Cardiovascular Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.


Background: Given the potential anti-ischemic effects of allopurinol, we aimed to assess whether allopurinol administration may reduce myocardial injury following non-ST elevation myocardial infarction (NSTEMI).

Methods: A randomized clinical trial (RCT) was conducted on 100 individuals with NSTEMI.The intervention group (n=50) received 600 mg oral allopurinol at the time of diagnosis ofNSTEMI, followed by 300 mg every day for two next days and the standard treatment of NSTEMI, while the control group (n=50) received only the standard treatment. Serum concentrations of cardiac troponin I (cTnI) were measured at baseline, and 8, 16, 24, and 32 hours after the treatment.

Results: The baseline demographic and clinical data of the patients were not statistically different between the intervention and control groups (all P > 0.05). The comparing estimated marginal mean ± standard error for cardiac troponin I (cTnI) levels revealed no significant difference between the study groups (2.93 ± 0.27, 2.25 ± 0.27; P=0.082). The linear mixed model results showed that the interaction of time and group was not statistically different (P=0.751). Moreover, there was a decreasing trend over time for cTnI in both groups (P=0.039).

Conclusion: The present pilot RCT did not support the potential cardio-protective benefits of allopurinol administration on decreasing myocardial injury following NSTEMI.

Keywords: Allopurinol, NSTEMI, Myocardial injury, Inflammation, cTnI
First Name
Last Name
Email Address
Security code

Abstract View: 240

Your browser does not support the canvas element.

PDF Download: 115

Your browser does not support the canvas element.

Submitted: 04 Jan 2021
Revision: 14 Mar 2021
Accepted: 18 Mar 2021
ePublished: 31 Mar 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)